Corona Virus Disease 2019
Conditions
Interventions
Experimental group:Xuanfei Baidu granules
Control group:Placebo
Sponsors
Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
5 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Asymptomatic and mild COVID-19 patients. The diagnosis criteria were referred to COVID-19 Diagnosis and Treatment Protocol (Trial Version 9); 2. Informed consent patients.
Exclusion criteria
Exclusion criteria: 1. Accompanied by serious underlying diseases affecting survival, including uncontrolled and clinically significant heart, kidney, digestive, blood diseases, neuropsychiatric diseases, immune diseases, metabolic diseases, malignant tumors, severe malnutrition, etc.; 2. Allergic constitution, allergic to the drug components involved in the treatment plan; 3. pregnant or lactating women; 4. Unable to cooperate in mental state, suffering from mental diseases, having no self-control and unable to express themselves clearly; 5. Participating in other clinical trials; 6. According to the judgment of the investigator, there will be patients whose efficacy and safety evaluation will be affected by complications of enrollment or poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The ratio of turn to moderate or severe type COVID-19;Time of nucleic acid turn to negative;Immunity outcome;Clinical symptoms score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood routine;Biochemical indexes; | — |
Countries
China
Contacts
Public ContactJunhua Zhang
Tianjin University of Traditional Chinese Medicine
Outcome results
None listed